
    
      This is a randomized, multicenter, phase 3 study to evaluate the efficacy and safety of
      sintilimab combined with ramucirumab as compared to stand of care chemotherapy for the
      first-line treatment of PD-L1 positive, unresectable locally advanced or metastatic gastric
      or gastroesophageal junction adenocarcinoma.

      The primary endpoint of this study is OS of the ITT population.
    
  